Singulus Technologies (SNG) Q3 2025 earnings summary

Executive summary

• Sales for the first nine months of 2025 were €44.3 million, down from €61.0 million year-over-year; Q3 sales were €13.0 million, compared to €20.3 million in Q3 2024.

• EBIT for the first nine months was minus €2.5 million, compared to €1.9 million in 2024; Q3 EBIT was minus €1.2 million versus €0.6 million last year.

• Order intake for the first nine months was €30.9 million, significantly lower than €70.8 million in 2024; order backlog as of September 30, 2025, was €64.0 million.

• Freely available liquidity as of September 30, 2025, was €5.1 million, down from €11.3 million a year earlier.

Financial highlights

• Gross margin for the first nine months was 32.5%, slightly up from 32.3% in 2024.

• Q3 2025 sales were €13.0 million, down from €20.3 million in Q3 2024.

• EBIT for Q3 2025 was minus €1.2 million, compared to €0.6 million in Q3 2024.

• Order intake in Q3 2025 was €9.8 million, compared to €18.5 million in Q3 2024.

Outlook and guidance

• Annual sales forecast for 2025 adjusted to €65.0–80.0 million due to delayed large orders.

• EBIT for 2025 expected between minus €4.5 million and plus €0.5 million.

• Positive trends anticipated in the Semiconductor and Life Science segments, with new contracts expected soon.